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Considerable ethical debate surrounding the risks and benefits of Phase I
oncology trials is based on older response and toxicity data that does not account for
recent changes in the types of agents and trial design. This study aims to not only update
these data, but to investigate the impact of novel trial designs on various clinical
outcomes.
We performed a review of the literature using the Medline database. Part I
included nearly all phase I trials published in 2002. Part II identified phase I studies of
cytotoxic agents alone, published from 2002 through 2004.
221 Phase I oncology studies, consisting of 6,008 patients, were studied in Part I,
while 149 studies, comprising 4,532 patients, were analyzed in Part II. Overall, the
response rate for Phase I oncology trials in 2002 was 19%, the mortality rate was 1.1%,
and the rates of severe hematologic and non-hematologic toxicities were 19% and 22%,
respectively. “Classic” phase I trials of single agent cytotoxic drugs accounted for only
18% of trials, while more than half (55%) included at least one FDA approved therapy.
The response and toxicity rates varied with the class of agent (e.g. cytotoxic, biologic,
vaccine), and the combinations of agents (e.g. approved, investigational) studied.
Only 34% of studies utilized aggressive dose escalation schemes, 22% permitted intrapatient dose escalation, and only 28% enrolled fewer than 3 patients to any dose level

before proceeding to the next higher dose level. Studies that allowed intra-patient dose
escalation or used fewer than three patients per dose were not associated with rates of
response or toxicity that differed from trials using a more “traditional” design, nor did
they increase the percentage of patients who received the recommended phase II dose.
However, aggressive dose escalations were associated with increased rates of both
hematologic (17% vs.10%) and non-hematologic (17% vs. 13%) toxicity for participating
patients without increasing response rates. None of these novel design strategies were
associated with a smaller patient requirement.
Phase I oncology trials represent a spectrum of different classes of agents and
design strategies that are often associated with distinct clinical outcomes. Accounting for
this variety is critical when evaluating their risk-benefit profiles and ethics. While some
innovations in trial design do not appear to be any more helpful or harmful than standard
methods in phase I trials of single agent cytotoxic drugs, using aggressive dose
escalations may, in fact, be more hazardous for patients. These findings highlight the
need for continued effort towards improving trial design and its impact on our patients.
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INTRODUCTION
Cancer remains the second leading cause of death in the United States, claiming
the lives of more than 550,000 annually. Despite the many advances made over the past
several decades, there is still a continual need to develop new anti-cancer therapies. In
fact, as cancer research has become a national priority, the number of new anti-cancer
therapies in development each year exceeds all other classes of therapeutics.1
For an investigational anti-cancer drug to be approved for use in the U.S., it must
endure three phases of clinical trials. After a compound has shown promise in preclinical
testing, an agent is administered to humans for the first time in a phase I oncology trial.
This is primarily a dose finding study in which the highest dose that has an acceptable
safety profile is identified and recommended for further testing. The drug then proceeds
to a phase II trial in which it is tested for both safety and efficacy, or how well the tumor
responds to the therapy. If the trial reveals at least a moderate response rate, the drug will
proceed to a phase III trial, which requires the participation of greater numbers of patients
in multiple centers and is conducted as a prospective randomized controlled trial
comparing the new therapy to the current standard of care. If the results demonstrate a
substantial benefit in overall survival, or reduced cancer suffering, with an acceptable risk
of toxicity, the drug will likely receive final approval.2
As first in human trials, phase I clinical oncology trials play a vital role in
translating laboratory science into therapies that may reduce cancer morbidity and
mortality. Traditionally, phase I oncology trials begin by administering a small dose of
the experimental agent, typically 10% of the dose that would be lethal to 50% of exposed
rats or dogs, to a group of 3-6 patients. Subsequently, cohorts of patients receive

increasing dosages, first by 100%, then 66%, 50%, 40%, 33% based on a “modified
Fibonacci” protocol. In addition, patients are usually restricted to their designated dose
levels and may not receive higher doses of the investigational agent even if they
experienced no significant toxicity. The trial ends when severe, or life threatening
toxicities (i.e., dose limiting toxicities, or DLTs) are experienced by a large fraction of
patients at a given dosage level. The dose just below this maximum tolerated dose
(MTD) is generally recommended for phase II efficacy studies. These studies often
gather pharmacokinetic information as well, to help guide future dosing schedules.3, 4 It is
important to recognize that phase I trials are also used to evaluate established therapies in
new areas of clinical application (ie. a new cancer type) and are not restricted to agents
that have never before been used in humans.
Ethical concerns have been raised regarding the nature and design of phase I
oncology trials. In order to better appreciate these viewpoints, it is important to first
review some of the basic ethical issues involved in clinical trials in general.

Ethics of Clinical Trials
The primary objective of clinical research is to further our understanding of
science and/or improve the health of a population. To accomplish this, clinical trials
enroll research participants who, at least in some sense, serve as a means towards
obtaining results that can be applied towards society at large. Because trials often times
include a risk of harm to patients, clinical trials leave room for exploitation.5-7 As such,
sets of criteria have been formulated against which the ethicality of a research trial can be
gauged. For example, Emanuel and colleagues identified seven elements that need to

exist in order for a trial to be ethically justified. These include value, scientific
validation, fair subject selection, informed consent, favorable risk benefit ratio,
independent review and respect. Consequently, a trial would have to demonstrate its
potential benefit to the scientific community and/or society at large according to rigorous
scientific methodologies; offer participating patients potential for benefit that is
commensurate, or greater than, the risk of harm; recruit patients equitably only after they
understand the details of, and have freely agreed to participate in, a given trial; provide
them with continued care and monitoring and allow for their withdrawal at any time, for
any reason.6

Ethics of Phase I Oncology Trials

Phase I oncology trials present a unique challenge. Patients have usually failed
conventional therapies and are dying of a disease that is incurable with standard methods.
Agents used in phase I trials, however, are often tested for the first time in humans
without extensive knowledge experience with their potential toxicities. Also, a narrow
therapeutic window often characterizes cancer therapies; doses most likely to produce
responses are also likely to produce toxicity.
Two primary ethical challenges have been charged against these trials. The first
is based on the assumption that patients do not fully understand the nature of phase I
studies and that they are primarily motivated by a misplaced hope of deriving clinical
benefit from the investigational agent.8 Several surveys have confirmed this
phenomenon.9, 10 Also, while dedicated to the best interests of their patients, physician-

scientists may have competing interests in conducting trials expeditiously that will yield
scientifically meaningful results. Consequently, even assuming the utmost integrity o the
part of the physician, the interests of the clinician and the patient may diverge.11
Physicians may also be able to capitalize on patients’ desperation and place undue
emphasis on the potential benefits of participation, thereby perpetuating, albeit perhaps
inadvertently and/or subconsciously, the “therapeutic misconception.” This term
characterizes the belief that the primary objective of a given trial is to directly benefit the
research participant when this is, in fact, not the case. This concern is not only limited to
physician communication, but informed consent forms themselves have been implicated
in this misrepresentation.12-16
The accuracy of these critiques have been questioned. Horng and colleagues
found that consent forms do a fairly good job of conveying the dose finding nature of
phase I trials, their associated risks and the unlikely prospects of deriving significant
benefit.17 Whether this translates into better patient understanding remains a question. A
recent review found that the most effective means of ensuring adequate patient
understanding before enrolling on a trial was having more time to discuss the details of
the trials with the physician and/or researcher and that doing so was a more effective
intervention than improving informed consent forms.18
The second fundamental ethical problem stems from the supposition that these
trials have an inherently unfavorable risk-benefit ratio for patients on account of the
substantial risk of harm they present to patients with little chance of deriving any clinical
benefit.3, 4, 19-21 Our study focuses on this concern. Because these trials include dose
escalations that often start at a relatively low dose, slowly increase, and prohibit

individual patients from receiving higher doses, regardless of how he/she is tolerating the
agent, investigators have claimed that too many patients are treated at “sub-therapeutic”
dose levels.8 That is, because investigational agents have been shown to most often be
biologically active (ie. produce tumor responses) between 80%-120% of the eventual
recommended phase II dose, patients who receive lower doses of the drug are unlikely to
be exposed to even potentially therapeutic doses.22 In fact, an older study by Estey and
colleagues found that only 40% of participants received biologically active doses.23

Response and Toxicity Data in Early Meta Analyses

Several meta-analyses examined objective response rates experienced by patients
who participated in phase I oncology trials. These earlier studies looked at trials
published in the 1970s and 1980s and found objective response rates around 4%, most of
which were partial or minor responses.22-25 While clinical benefit was rare, the potential
risks associated with participating in these trials was significant. These studies found a
toxic death rate of 0.5%, that is 5 out of every 1,000 patients participating in phase I
studies experienced an early death due to the toxic effects of the investigational agent.24
Although not recorded in these studies, the rate of serious, or life threatening toxicity
could be presumed to be substantially higher. This increased risk of serious toxicity, or
death, coupled with the presumed inconveniences and costs of frequent blood draws,
medical appointments, radiologic evaluations and biopsies in exchange for a small chance
of benefit all bolster the position that these trials are not in the best interests of patients,
and therefore, unethical.26

In 2003, Agrawal and Emanuel presented a contemporary review of the ethics of
these trials and challenged this perspective.19 They identified several limitations to the
available aforementioned data. First, the data was outdated, as the trials included in the
meta-analyses were completed in the 1970s and 1980s. Second, phase I studies of agents
already approved by the Food and Drug Administration (FDA), or studies using more
than one agent were not included in these analyses. Third, neither newer compounds
being evaluated, such as antibodies, vaccines, immunotoxins, and anti-angiogenesis
factors, nor improved supportive care measures, were reflected in the commonly cited
response rate of 5% and mortality rate of 0.5%. These old data did not seem to reflect the
increasing complexity and heterogeneity that characterize current phase I clinical trials.
This review also highlighted the potential psychological benefits to participating in a trial
either because of the frequent physician contact, or as an act of defiance and battle
against one’s illness. George Zimmer, a professor of English who participated in several
phase I oncology trials, explained his motivation as follows:
Letting a patient choose the poisons (under professional guidance) adds
something to the will to struggle. We who are struggling to escape cancer
do not, obviously, want to die of it. We do prefer death in the struggle to
life under cancer's untender rule. The enemy is not pain or even death,
which will come for us in any eventuality. The enemy is cancer, and we
want it defeated and destroyed…Just before assaults on fortified positions,
U.S. Civil War soldiers would pin their names and addresses to their
uniforms to make it easier for the body-sorters to do their work after the
battle. Patients going into these modified protocols could likewise place
their names on specific protocol adjustments. Survivors could then
proclaim: This is how I wanted to die-not a suicide and not passively
accepting, but eagerly in the struggle.27
Two meta analyses subsequently sought to update and expand upon the data
derived from the older studies. The first was published in JAMA in 2004 by Roberts and

colleagues.1 They identified 213 single agent trials of non-FDA approved drugs the
results of which were originally submitted to annual meetings of the American Society of
Clinical Oncology (ASCO) from 1991 through 2002. They reported an overall toxic
death rate of 0.54%, which had decreased from 1.1% in 1991-1994, to 0.06% between
1999-2002. They also were the first to report the overall rate of serious (grade 3-4)
toxicity experienced by patients at 10.3%. To their surprise, they reported an overall
objective response rate of only 3.8%, though they surmised that by excluding trials that
tested approved agents, or a combination of agents, they had likely “biased downward”
their response rate estimates. They did, however, include non-cytotoxic agents and found
that they accounted for almost half of all of the trials. In addition, multivariate analysis
showed that the odds of a patient dying from a biologic/targeted agent were one fourth
those of a patient dying from a cytotoxic agent (OR, 0.25; 95% CI 0.10-0.65; p=.005),
though they did not differ in predicting response.
The second meta-analyses was published in the NEJM in 2005 by Horstmann and
colleagues.28 They analyzed 460 trials sponsored by the Cancer Therapy Evaluation
Program of the National Cancer Institute (NCI) between 1991 and 2002. Their study
offered the first published analysis that included FDA approved therapies, as well as trials
which used a combinations of agents. They found an overall objective response rate
(complete and partial response, or CR+PR) of 10.6%, with a CR of 3.1% and a PR of
7.5%. When patients who experienced disease stabilization were included, the response
rate climbed to 34.1%. And while studies that tested single investigational agents were
associated with an overall response rate of 4.2%, this percentage improved to 7.1% for

studies that used multiple investigational agents, and to 27.4% for studies testing FDA
approved therapies.
The rates of toxicity also varied according to the types of agents that were used.
Overall toxic deaths occurred in 0.49% of all patients, similar to all previous published
reports, and overall 14.3% of patients experienced a grade 4, or life threatening, toxic
event. The rates were highest in trials using cytotoxic agents at 17.4%, while vaccine
trials had no grade 4 toxic events. And the rate varied even within the cytotoxic class,
with 15% of patients on trials testing single agents experiencing a severe toxicity as
compared to 34% of patients who received FDA approved therapies while on trial.
After enhancing our understanding of the objective risks and benefits of phase I
oncology trials, especially through an appreciation for the heterogeneity of these trials,
we decided to reexamine the ethical arguments presented above. Indeed, Agrawal and
Emanuel were correct in their speculation that modern response and toxicity rates would
likely be different than those found in the 1970s and 1980s. The rate of serious toxicities
is considerable, estimated between 10-14%, and the death rate appears to be stable
between 0.5-1%. However, overall objective response rates have increased from about
4% to between 10-20%, with almost half of all patients deriving some clinical benefit
(CR+PR+SD), largely due to the increasing use of FDA approved agents and/or
combinations of agents. One could certainly argue that based on the updated data, the
risk-benefit ratio of phase I oncology trials may be more favorable than was originally
thought.
A careful review of the data, however, reveals that trials that tested single
investigational agents reported response rates around 4%, similar to the data from older

studies. Cytotoxic agents were also associated with higher toxicity than targeted
therapies or vaccines. It would therefore seem that while overall, the risks and benefits of
phase I oncology trials appeared to have changed for the better in recent years, this may
not apply to trials involving single cytotoxic agents, especially investigational ones.
Perhaps more fundamentally, these updated data do not address some of the most
compelling ethical charges against phase I oncology trials. Largely due to constraints
imposed by study design, many patients receive “sub-therapeutic” doses of an agent, yet
are still exposed to the risks of participating. Several components of the classic phase I
trial design may contribute to this phenomenon. Firstly, intra-patient dose escalation, or
the ability of a patient who is tolerating an agent well to receive a higher dose, is usually
prohibited, which confines patients enrolled earlier in the trial to the lowest, and probably
inactive, doses. There appears to be an inherent injustice in this design, insofar as
patients with few, if any, alternative therapies who are tolerating the agent well do not get
the chance to benefit from the drug. A recent survey showed that most patients, in fact,
desire to retain control of their destiny and are willing to endure higher risks for the
possibility of clinical benefit.29 These trials also classically require 3-6 patients in each
dose level, even the initial ones which are often several dose levels below the
recommended phase II dose. Both of these design limitations almost guarantee the need
for a significant number of patients to fill the lower dose levels in which they are less
likely to experience serious toxicity, but also less likely to experience a significant
response. Lastly, the ““modified Fibonacci”” escalation scheme is often times too
conservative for agents that prove to be relatively benign during early dose levels.

Aggressive Design Strategies: Current Data

Based on these observations, there has been a concerted effort over the past
decade or so to devise more innovative dosing strategies that will decrease the number of
patients receiving lower doses of drugs on trial. In 1997, Simon and colleagues at the
NCI suggested a variety of accelerated titration designs, including allowing for
intrapatient dose escalation, using fewer patients in earlier dosage levels and repeatedly
increasing drug dose levels by 100%. The trial would revert back to traditional designs
when some patients experienced toxicity. The goals of these newer designs were
twofold: to increase the number of patients who received doses presumed to be
biologically active, usually the recommended phase II dose, and to reduce the number of
patients needed to complete a phase I trial. They fit a stochastic model to data collected
from 20 completed phase I trials and found that these methods increased the percentage
of patients receiving higher doses and decreased the total number of patients required for
a trial. Objective response outcomes were not considered.30
Other novel designs include sophisticated statistically based models, such as the
continual reassessment method (CRM) and its variants, which employ certain predictions
in designing a dose escalation which is then continually modified throughout the trial
based on encountered toxicities.31, 32 Using pharmacokinetic, biologic and radiographic
endpoints has also been suggested for newer targeted biological therapies, rather than the
traditional toxicity endpoints of classic cytotoxic chemotherapeutic drugs.33-36
While the use of these latter design strategies have been studied fairly extensively,
surprisingly very little research has been published examining the prevalence of the three

novel design strategies suggested by the NCI group and their impact on response and
toxicity rates, the percentage of patients who receive recommended phase II doses and
the overall number of patients needed to complete a trial.
Dent and Eisenhauer reviewed 46 single agent trials of cytotoxic compounds that
were published between 1993 and 1995.37 They found that the majority of trials still used
a “modified Fibonacci” escalation, while only 3/46 doubled the dose until toxicity was
seen. Furthermore, they found that only 39% of patients received the recommended
phase II dose in trials that tested agents being administered for the first time in human as
compared to 57% of patients who received drugs that had previously undergone phase I
study. They did not examine the usage of intra-patient dose escalation or fewer patients
per dosage level. In 1998, a workshop of phase I investigators was convened to review
their experiences with novel phase I designs. They describe two phase I trials of the
same investigational agent that were being conducted simultaneously at two different
institutions. One used a traditional design while the other allowed a single patient per
dose and intra-patient dose escalation until toxicity was reached. The latter design was
able to accomplish 8 dose escalations with only 15 patients, compared to just 3 dose
levels that required 12 patients in the study which used a traditional design.38
Unfortunately, the two large meta-analyses published recently placed little
emphasis on this issue. The only data that was gleaned was that only 29% of the studies
included in the Roberts paper allowed intra-patient dose escalation, and doing so was
associated with greater odds of experiencing response in multivariate analysis (OR 1.7).
There were no differences between these types of studies in predicting toxicity, and they

did not evaluate the endpoints of patients receiving the recommended phase II dose, or
the average number of patients needed to complete a trial.1
Appropriately, the editorial that accompanied that paper included the subtitle, “A
Case for More Innovation,” in which the authors argued that single agent trials of
cytotoxics in particular are in need of new design strategies that can improve the
opportunity for patient benefit, especially in light of their consistently minimal response
rates. They specified the design strategies introduced in the NCI study as hopeful
possibilities.39

Rationale for Current Study
In trying to modernize and update the response and toxicity data of phase I
oncology studies, we designed a project with Agrawal and Emanuel in which we would
perform a meta analysis on phase I oncology studies published in 2002. Our points of
interest included cataloging the various types of agents used in phase I trials, including
FDA approved agents and the use of multiple drugs, documenting response and toxicity
rates, and investigating the impact that geography and study sponsorship had on these
data. Our hypothesis was that, in fact, the types of agents used in phase I oncology
studies had changed over the past decade and that the variety of different categories of
therapeutic options would yield a spectrum of response and toxicity results rather than a
uniform picture. This study would also be able to add to the two previous meta-analyses
by providing a comprehensive data set, including the variety of agents and trial types
looked at by Horstmann et al, as well as geography and sponsorship data looked at by

Roberts et al, in a more recent cohort of studies. The results of this study are included in
PART I of the original research component of this thesis.
Because ethical questions would remain even after we accumulate data from Part
I, we proceeded towards an analysis of novel dosing strategies. Their prevalence, as well
as their utility in improving the risk-benefit profile of these trials remains largely
unknown. We therefore set out to answer these questions and decided to focus on single
agent trials of cytotoxic agents, as they represent the ideal arena for the implementation
of these novel designs. However, as our data set from Part I of this thesis was
insufficient, we decided to expand our body of studies to include those published in 2003
and 2004 with the hopes of increasing our sample size and the power of our analysis.
This comprises Part II of this project.

METHODS

This section will detail the methods of two distinct components of our study,
entitled part I and part II. The first part of this study focused on identifying the various
categories of agents (e.g. cytotoxic, biologic, vaccine) and types of agents (e.g.
investigational, FDA approved) used in phase I oncology trials along with their
associated rates of response and toxicity. The second component aimed to identify the
prevalence of several novel dose escalation design strategies and their impact on a variety
of clinical endpoints, in a more uniform sample of single agent trials of cytotoxic drugs.

Search Strategy
We performed a review of the literature using the Medline database. Part I
included nearly all phase I trials published in 2002. Part II identified phase I studies of
cytotoxic agents, published from 2002 through 2004. Their respective search criteria are
included as an appendix (appendix 1). Overall, the search criteria were purposely
designed to be broad so as to include the vast majority of published phase I oncology
trials.
The primary reason for exclusion was that studies were not standard phase I
chemotherapy trials. This included trials for which: (1) the primary trial objective was
not to determine safety; (2) the experimental treatment was not intended to have
independent or synergistic anti-cancer effects; (3) there was not sufficient differentiation
between data from a Phase I and Phase II portion of the study; (4) the trial was not
performed on human subjects; (5) the experimental protocol included radiation or
photodynamic therapy; (6) the paper did not directly report the results of a clinical trial;
(7) the paper was not a complete report; and (8) the trial was testing a supportive care
rather than an anti-cancer intervention. For Part II, studies were also excluded if more
than one agent was used in the study and/or if the investigational agent was not cytotoxic
(ie. immunotherapy, signal transduction inhibitor, angiogenesis inhibitor, gene therapy,
vaccine). Our search for Part I yielded 301 studies, of which 221 met all inclusion
criteria. Of the 955 studies originally identified in Part II, 149 were included (Figure 1).

Data Extraction
Two investigators independently extracted the pertinent information using a
formal abstraction instrument that included number of patients, patient gender, patient
age ranges, prior therapy history, toxicity and response data, dose escalation strategy, the
allowance of intra-patient dose escalation, minimum patients per dose, class and approval
status of agent and the number of patients who received the agent at or above the
recommended phase II dose at least once. For Part I, all results were compared and all
discrepancies were resolved by consensus. For Part II, in a comparison of the abstracted
data from 15% of the studies, the discrepancy rate between data points was found to be
less than 5% overall. Discrepancies were reviewed and resolved by the two investigators.
For Part I, trials were grouped into six different categories according to
mechanism of action of the investigational agent(s): 1) chemotherapy/cytotoxic agents,
2) immunomodulators, 3) receptor or signal transduction inhibitors 4) anti-angiogenesis
agents, 5) gene-therapies, and 6) vaccines. Treatments were categorized into three
groups: (1) non-chemotherapy agents, (2) FDA-approved chemotherapies, and (3)
investigational chemotherapies. Dosing strategies comprised three distinct categories: 1)
traditional, according to a ““modified Fibonacci”” protocol; 2) conservative, in which the
initial dose increase was less than 100%; and 3) aggressive in which at least the first two
dose increases were by 100%. Study design was obtained from the methods section of
each published trial. Intra-patient dose escalation was only recorded as allowed if the
study explicitly indicated as such in the methods section.

Study sponsorship was assessed in the trials conducted in the U.S. because
information on study sponsorship was reported in only 30% of the studies conducted in
Europe and the other countries. Among U.S. studies, study sponsorship was coded into
three categories: 1) industry, (this does not include instances in which only a drug was
provided with no other financial support), 2) government, foundation or other non-profit,
and 3) study support was not indicated.
The location of the first author’s employing institute or corporation was coded
into three categories: 1) U.S., 2) Europe, or 3) other.

Outcome Definitions

Response data included the number of patients who experienced a complete
response (CR), partial response (PR) and stable disease (SD) according to standard
definitions. For solid tumors, CR was defined as complete radiographic disappearance of
the lesion at 4 weeks, a PR was 50% or greater decrease in the sum of the products of the
perpendicular diameters of all measured lesions at 4 weeks, progressive disease was
defined as an increase of these tumor dimensions by more than 25%, any new lesion, or
any definitive increase in tumor size and SD included anything that did not qualify as
progressive disease or a PR, including “minor responses.”40
Toxicity data included possible or probable toxic deaths, non-hematologic
toxicity, and hematologic toxicity. Deaths explicitly reported as toxic deaths or other
deaths in the study not expressly reported to be unrelated to the intervention (ie. possible,
probable) were counted in the toxic death rate. All toxicity grades follow the standard

definitions outlined in the Common Toxicity Criteria v2.0 (1999) and/or the Common
Terminology Criteria for Adverse Events v3.0 (2003) as part of the Cancer Therapy
Evaluation Program (CTEP) of the National Cancer Institute. Grade 3/4 non-hematologic
and grade 4 hematologic toxicity were recorded because these determine toxicity rules for
dosing modification in Phase I oncology studies. For this reason, grade 3 febrile
neutropenia was included as a hematologic toxicity. Alopecia was not included as
toxicity.

Statistical Analysis

For each study, response rates, mortality rate, and toxicity rates were calculated
based on the published data and exact confidence limits estimated. For some rates, data
were not available and so the rates for these studies were treated as missing at random.
For grade 3-4 non-hematologic and grade 4 hematologic toxicities, some of the studies
only provided information such that the minimum and maximum number of patients
incurring the toxicity could be ascribed (i.e. these studies reported the number of toxicity
events rather than number of patients with toxicity events). In these cases, we used a
weighted approach for estimating the true number of patients who had experienced a
toxicity, where the estimated number of toxicities (ti) is defined as:

ti = 0.75 × mini + 0.25 × maxi
For example, in one study it could be assumed that at least six, but no more than 10
patients, had grade 4 hematologic toxicities. The imputed number of grade 4
hematologic toxicities for this study was 7 patients. This estimate is more conservative

and also more appropriate than simply taking the average of the minimum and maximum.
The distribution of toxicities across studies tends to be skewed: the bulk of the toxicity
rates are lower values, while higher values tend to be outliers, indicating that an estimate
of the number of toxicities within any given study should tend to favor smaller values.
Meta-analysis techniques were used for data analysis. A beta-binomial model
was used for estimating rates (i.e., proportions) across studies. This model allows for
extra-binomial variability, as would be expected in a meta-analytic setting. For the
multiple regression models, a random effects grouped logit model was used. The model
is essentially a generalized linear model from the binomial family with logit link where
studies are ‘groups’ (i.e., the unit of analysis is study) and a random effect is included for
each study. Associations were considered significant if the null value was outside of the
95% credible interval of a parameter. For multiple regression models, we considered
covariates that showed significance in simple regression models. Multiple regression
models were explored by including main effects and pairwise interactions, and then
removing insignificant effects and interactions one by one. These models were not fit for
CR and for mortality because the event rates were very low and results were unstable.
For Part I, the WinBugs, version 1.4, software was used, which implements a
Bayesian estimation approach, for model estimation with diffuse priors in all metaanalyses.41 Reported point estimates are the means of the posterior distributions of the
parameters, and the 95% credible interval for a parameter is the 2.5th and 97.5th
percentiles of its posterior distribution. For Part II a Markov chain Monte Carlo
approach was implemented for estimating parameters. Each of the coefficients in the
regression model was assumed to have a Gaussian diffuse prior, and random effects were

assumed to have a normal distribution with variance τ2, where the hyperprior for 1/τ2 is a
diffuse Gamma distribution. WinBugs within OpenBugs 2.01 was used for model
estimation. For each analysis, a burn-in period of 5000 iterations was performed. Then
an additional 20000 iterations were run where every 5th iteration was saved for inference.
Multiple chains were run for each analysis and traceplots were explored to ensure
convergence. No convergence problems were encountered. Point estimates were defined
as the posterior mean, 95% credible intervals as the 2.5th and the 97.5th percentiles of the
posterior distribution, and tail probabilities as the (two-sided) proportion of area under
the posterior distribution that is more extreme than the observed data. The tail
probabilities and 95% credible intervals can be interpreted similarly to p-values and 95%
confidence intervals.

RESULTS

PART I: Response Rates and Toxicities in Phase I Oncology Studies in 2002
The final study sample consisted of 221 Phase I oncology studies published in
2002, which included 6,008 research participants assessable for toxicity and 5,362
assessable for response (Table 1). Almost all of the enrolled participants had an ECOG
performance status of 0 or 1, that is they had normal physical activity or only need extra
rest less than 50% of the day.42 Half of the participants were male, the mean age was
60.5, 55% had prior chemotherapy, and 20% had prior radiotherapy.

The majority of the studies were chemotherapy trials (173 trials, 78%) involving
4,268 patients assessable for response. Vaccines were the second largest group (13 trials,
6%), and gene therapy the smallest group (3 trials, 1%) of trials. Overall, 40 (18%) of the
studies were “classic” Phase I studies in that they tested a single, non-approved cytotoxic
agent. A majority of the published Phase I studies (121, 55%) used only commercially
available (ie. FDA approved) agents (Table 2).

Response Rates
Considering all 221 studies, the mean overall response rate (CR + PR) was 19%
(95% CI: 17, 22). The complete response rate (CR), in which the tumor disappeared, was
estimated to be 3.8%. When adding “minor responses” and stable disease to partial and
complete responses, the total rate of clinical benefit was estimated to be 48% (Table 1).
The response rates differed considerably according to the type of Phase I agent(s)
assessed (Table 1 and Figure 2a). The estimated overall CR + PR rate was 21% for
chemotherapy trials; while for vaccine trials it was just 2.9% (Table 1). The response
rates also varied considerably according to the type of trial (Table 2). For nonchemotherapy agents, trials with a single investigational agent alone had an estimated CR
+ PR rate of 7.7%, while this figure was 4.8% for chemotherapy agents. Studies using
only FDA approved agents had an estimated response rate of 29%, and those with a
combination of investigational and commercially available agents had an estimated
response rate of 14%.
After adjusting for other factors, including sponsorship, solid vs. non-solid tumor,
and percentage of patients treated with prior therapies (Table 3), multiple regression

analysis showed that chemotherapy studies using FDA approved agents had significantly
higher response rates than non-chemotherapy studies (OR= 5.16, 95% CI 2.72-9.58).
Chemotherapy studies using investigational agents, on the other hand, had lower response
rates than non-chemotherapy studies (OR = 0.77, 95% CI 0.36-1.55), though statistical
significance was not achieved.

Death and Toxicities
The overall mortality rate across all 221 Phase I studies was 1.1% (95% CI 0.81.6) (Table 4). Studies of cytotoxic agents had a mortality rate of 1.3%, whereas trials
involving vaccine and anti-angiogenesis agents had no observed deaths (Figure 2b). The
estimated mortality rate was highest in studies that included FDA approved agents
(1.6%), and lowest in studies of single, non-cytotoxic investigational agents (0.4%)
(Table 4). Phase I studies with a combination of commercial and investigational agents
had an estimated mortality rate of 0.9%. “Classic” phase I studies had a mortality rate of
1.0% (95% CI 0.6%- 1.6%).
The overall grade 3/4 non-hematologic toxicity rate was estimated to be 22% and
the grade 4 hematologic toxicity rate was 19% (Table 2). Bivariate analysis showed that
grade 3/4 non-hematologic toxicity was very similar for chemotherapy trials (19%) and
trials testing non-cytotoxics (18%), with the exception of vaccine trials (0.9%) (Figure
2c). Rates of serious non-hematologic toxicity were also similar across trials regardless
of whether trials used commercial agents alone, investigational agents alone, or a
combination of agents. By contrast, grade 4 hematologic toxicity rate was higher for both

investigational chemotherapy trials relative to investigational non-chemotherapy trials
(2.8% vs. 10%), as well as trials with commercial agents (29%) (Table 2).
Multiple regression analysis confirmed these associations. While both
investigational (OR = 5.26, 95% CI 1.99- 14.0) and FDA approved (OR = 18.9, 95% CI
7.92- 48.4) chemotherapy agents were associated with dramatically higher rates of
hematologic toxicity than non-chemotherapy agents, the risks of non-hematologic
toxicity were similar for non-chemotherapy agents and investigational chemotherapy
agents (OR = 1.09, 95%CI 0.64-1.88). However, the multivariate model also found that
FDA-approved chemotherapy agents appeared to be associated with a slightly higher rate
of grade 3/4 toxicities (OR = 1.62, 95% CI 1.04-2.64) relative to non-chemo
investigational agents (Table 3).

Sponsorship
Trials sponsored by for-profit and non-profit organizations had similar response
rates, 17% and 16% respectively (Table 5 and Figure 3a). However, the mortality rates
did vary across sponsorship. In crude bivariate analysis, for-profit sponsored studies had
a mortality rate of 1.4%, as compared to 0.7% for those sponsored by non-profits. Grade
3/4 non-hematologic toxicity did not vary between for-profit and non-profit sponsored
studies (Table 5b-d). However, multiple regression analysis showed relatively little
differences in response and toxicity rates in for-profit and non-profit trials after adjusting
for other factors.

Geography
There were variations in response rates according to the country in which the
study was conducted (Table 6). Studies in the U.S. had response rates of 14%, whereas
studies from Europe had response rates of 24%, and the remaining nations had a response
rate of 25%. The toxic death rate was 1.3% in the U.S., 1.1% in Europe, and 0.8% in the
remaining countries. Grade 3/4 non-hematological toxicity was 20% in the U.S., 25% in
Europe, and 18% in the remaining countries. Grade 4 hematological toxicity was 13% in
the U.S., 25% in Europe and 26% in the other countries. Multiple regression analyses
showed the higher response rate for studies from Europe as compared to those done in the
U.S. to be statistically insignificant after adjusting for other factors.

PART II: The prevalence and impact of novel design strategies in 2002-2004

Despite an updated knowledge of the rates of response and toxicity in Phase I
trials overall, aspects of the traditional design of these trials have been implicated as a
cause for many patients receiving “sub-therapeutic” doses, especially in single agent
trials of cytotoxic drugs. Novel design strategies have been introduced with the hopes of
improving the ethically questionable risk-benefit ratios of these trials, but little research
has been done to determine their prevalence and efficacy. We therefore set out to
investigate these questions in the second part of this study.
In 149 phase I studies published between 2002 and 2004 which assessed single
agent cytotoxic compounds, 4,350 patients were evaluable for toxicity and 4,027 were
evaluable for response (Table 7). Predominantly patients had solid tumors (90%), with
9% of studies including only hematological or lymphatic malignancies and 1% of studies
accepting patients with either solid or liquid tumors. While the toxic death rate was small
at 1%, there was a more significant incidence of serious, or life threatening drug related
hematologic (15%) and non-hematologic (17%) toxicity. The overall objective response
rate was 3% (CR + PR), which increased to 25% with the addition of stable disease as an
endpoint. Also, 60% of patients received a dose of the investigational agent that was at
or above the eventual recommended phase II dose.
As opposed to the first part of this study, most agents used in the phase I trials
included in this latter component of the study were investigational, while the FDA had
already approved only 26% of them. The majority (66%) of these studies used traditional
“modified Fibonacci” or even more conservative dose escalation schemes. Only 34% of

studies utilized aggressive dose escalation schemes, 22% permitted intra-patient dose
escalation, and only 28% enrolled fewer than 3 patients to any dose level before
proceeding to the next higher dose level (Table 8). Interestingly, the prevalence of
studies allowing intra-patient dose escalation or using aggressive titration designs
declined in 2004 from the rates seen in the previous year, while a greater percentage of
studies used fewer than 3 patients per dose in that year (Figure 4).

Trials Using Different Escalation Designs

Bivariate analysis revealed several important findings. Conservative titration
designs were associated with significantly higher hematologic (17%vs.10%, tail
probability (tp)=.01) and non hematologic (20%vs.13%, tp=.03) toxicity rates, as well as
higher response rates (CR+PR 6%vs.2%, tp=.002; CR+PR+SD 32%vs.21%, tp=.03) as
compared to the traditional ““modified Fibonacci”” design. Conservative designs also
resulted in the highest percentage of patients who received at least one dose of the
investigational agent at or above the recommended phase II dose (71%vs.46%, tp<.001)
(Table 8).
When comparing the use of aggressive titration designs to studies using
traditional designs, the former were associated with an increased risk of both hematologic
(17%vs.10%, tp=.01) and non hematologic (17%vs.13%, tp=.20) toxicity for
participating patients, although the finding for non hematologic toxicity was not
statistically significant. Importantly, response rates (CR+PR 1%vs.2%, tp=.53;
CR+PR+SD 23%vs.21%, tp=.79) and the percentage of patients receiving the

recommended phase II dose (55%vs.46%, tp=.18) showed no statistically significant
differences (Table 8).

Trials Allowing for Intra-patient Dose Escalation, Fewer Patients Per Dose

The two other novel design strategies, allowing intra-patient dose escalation and
using fewer than three patients in the initial dosage levels, revealed no statistically
significant differences in response rates, toxicities, or the percentage of patients receiving
the recommended phase II dose relative to the standards in their categories. The single
exception was an increased CR+PR+SD (28%vs.20%, tp=.03) in studies that did not
allow fewer than three patients in any given dose level, a finding that is of questionable
import (Table 8).

Trials with FDA-Approved Agents

We then analyzed studies using FDA approved agents. Our initial expectations
were that these agents would produce a better response rate, and that investigators might
be more conservative with their dose escalations given the already well-known
characteristics of the particular therapy. What we found was that, in fact, studies that
tested a drug that had already been approved by the FDA for another indication were
associated with increased objective response rates (CR+PR 10%vs.2%, tp<.001;
CR+PR+SD 40%vs.22%, tp<.001) as compared to investigational agents. In multivariate
analysis, no interaction was found between FDA approval and conservative dose

escalation design, as these two variables were independently associated with the
increased response (Figure 5). However, multiple regression analysis of the CR+PR+SD
endpoint revealed that these two trial types were independently associated with an
increased clinical response rate only in trials that used fewer than three patients per dose
early on. There did seem to be interactions, however, when these studies used the more
traditional design of 3 or more patients for every dose level (Figure 6). Interestingly,
increased tumor response to FDA approved drugs was not at the expense of a
significantly increased risk of hematologic (18%vs.14%) or non hematologic
(19%vs.16%) toxicity, although there did seem to be a trend in that direction.

Number of Patients Required Per Trials

Our final endpoint of interest was the average number of patients needed to
complete these phase I trials. If any of these novel designs could reduce this number,
their use could possibly limit the number of patients having to participate in, and be
exposed to the hazards of, phase I trials. What we found was that trials which used
conservative dose escalation designs required a lower average number of patients to
complete their trials than those that used aggressive dose escalations (26.2 vs. 33.9;
p=.04). The same was true of studies that tested FDA approved agents (25.2 vs. 32.3;
p=.02). However, none of the novel design strategies in question had any significant
impact on this endpoint as compared to “standard protocols” (Table 9).

DISCUSSION
Phase I oncology trials simultaneously embody some of the highest ideals of
medicine, and some of the most challenging ethical dilemmas faced in clinical research.
These trials serve as the bridge between the promises of laboratory research and powerful
therapies that help the sick and suffering. Yet, accomplishing this noble task requires the
use of patients as research subjects, from whom objective data can be ascertained. Unlike
clinical trials in general which often use healthy volunteers, phase I oncology trials enroll
patients with refractory cancer who have few therapeutic options and little hope. This
combination of patients in desperate circumstances and investigators who have an interest
in the scientific validity of their trials in addition to their patients’ well-being, presents a
scenario in which misplaced hopes and unjustifiable optimism can easily chart a course
towards unintentionally violating a basic principle of medical ethics, nonmalfeasance –
‘do no harm.’ Patients ought not be exploited, even for the sake of serving the greater
good. Participation in phase I oncology trials must be based on an adequate
understanding of the primary aims of the study - assessing the safety of an agent and
finding an appropriate dose to test in phase II trials - coupled with realistic expectations
regarding toxicity and response potential. Ensuring that this happens, either through
consent forms, consultations with physicians, or both, is often easier said than done.
Even when fully informed, phase I trials may present patients with a greater
likelihood of harm than benefit. Antitumor agents often present patients with substantial
risks of severe, even life threatening toxicity, which can be even more dangerous with
unknown, investigational agents. And while these toxicities occur in phase I trials,
historically, a majority of patients enrolled were treated at “sub-therapeutic” dose levels.

The risk-benefit ratios of these trials can only be favorable if patients facing toxicity also
have a genuine chance to benefit from these agents. An accurate knowledge of the rates
of response and toxicities, and the percentage of patients receiving therapeutic doses are
indispensable for patients to weigh the risks and benefits they face. Moreover, from the
vantage point of investigators, efforts must be made to continually improve the “research
system” and to strive to provide each patient with the opportunity to derive maximal
potential benefit from a drug on trial.
What are the overall risks of harm to patients participating in phase I oncology
trials? Our results show a toxic death rate of 1.1% overall. Despite this low overall risk
of toxic death, a significant percentage of patients did experience severe hematologic
(19%) and non-hematologic (22%) toxicity. While these rates were consistent between
different categories of agents for both toxic deaths and non-hematologic toxicities,
multivariate analysis confirmed that both FDA approved (OR = 18.9, 95% CI 7.92- 48.4)
and investigational (OR = 5.26, 95% CI 1.99- 14.0) cytotoxic agents were associated with
higher rates of hematologic toxicities than non cytotoxic agents. These data are
supported by their similarity to previous studies (Table 10) and are easily applicable to
contemporary patients insofar as they reflect trials conducted in an era of better
supportive care for much toxicity, including nausea, vomiting, pain, low blood counts and
infections.
Patients who participated in these trials also experienced significant tumor
responses to the agents under investigation. In fact, response rates seem to have
increased substantially from the 3-5% reported in earlier studies (Table 10). Objective
response rates were higher than previously reported (CR+PR 19%), with nearly half of all

patients experiencing some clinical benefit (CR+PR+SD 48%). These increases appear
to be at least partially due to the increasing use of non-cytotoxic agents, as well as FDA
approved agents (55% of trials) in these early clinical trials. Multivariate analysis
confirmed the response advantage to commercially available cytotoxic agents (OR= 5.16,
95% CI 2.72-9.58). Indeed, classic single agent trials of investigational cytotoxics, which
comprised only 18% of all trials, revealed modest response rates that were no higher than
those reported in previous studies (CR+PR 2-4%).
How to interpret these response and toxicity data in a way that can help an
individual patient considering participating in a phase I trial understand the associated
risks and benefits is in no way straightforward. There are several important elements that
must be considered.
Firstly, these data are aggregates of the responses and toxicities seen in hundreds
of trials, which tested scores of different agents, often in different tumor types. Phase I
trials have produced 98% response rates, as in the case of imatinib mesylate (Gleevac) in
patients with chronic myelogenous leukemia, while a study of a novel spicamycin
analogue resulted in more than 10% of patients suffering toxic deaths and another 50%
experiencing severe or life threatening toxicity.43, 44 Our response and toxicity data do not
apply to any individual phase I trial, but rather provides an estimate of the overall
prevalence of these endpoints.
Secondly, whether tumor responses actually translate into clinical benefit is
unclear.45, 46 Some contend that response rates are merely surrogate endpoints and do not
correspond to different survival outcomes.47, 48 In their reply to this position, Horstmann
and colleagues cite several studies that demonstrate relationships between tumor response

while on trial and survival, symptom improvement and quality of life endpoints.28, 49-51
While response rates are certainly an imperfect measure of clinical benefit, they do
appear to have clinical meaning.
How to interpret our response data is also complicated by our inclusion of the
non-traditional endpoint of disease stabilization. We believe the benefits of doing so are
two-fold. Firstly, disease stabilization captures the benefits of the drug in the form of
“minor responses” that are excluded due to an arbitrary definition of 50% or greater
tumor shrinkage needed to qualify as an objective response.52 Moreover, the proliferation
of biologic agents that function in a cytostatic capacity, along with continually improving
supportive care measures, argues for the value in measuring how well a drug can enable a
patient to live with a cancer that is not progressing.28, 53
In synthesizing our results, some guiding principles about how to assess the risksbenefit ratios of these trials emerge. First and foremost is the recognition that phase I
trials are not all the same. They encompass a wide array of agents and trial designs.
Therefore, one must consider the particular type of agent (e.g. cytotoxic, biologic,
vaccine), whether it is an investigational or approved therapy and whether it is being
tested alone or in combination with other agents. Next, in discussing likelihood of
response and toxicity, an investigator must convey some of the uncertainty as to their
interpretation. One must also incorporate the values and disposition of an individual
patient. Is his/her priority to avoid suffering, or is the goal to persist “eagerly in the
struggle” and try to overcome his/her disease to whatever extent possible? Of course, the
ability to effectively communicate these ideas in a way that empowers each patient to

decide whether or not the risk-benefit profile of a particular trial is favorable to him/her is
part of the difficult art of medicine.
Our appreciation for how different types of trials were associated with distinct
response and toxicity rates then led us to reexamine the need for improved trial design.
We demonstrated that while the overall response rate in phase I oncology trials had
significantly improved from previous reports, this was not the case for “classic” single
cytotoxic agent trials, which were associated with increased toxicity without the benefit
of increasing response rates. We, therefore, decided to study whether single agent
cytotoxic trials that used more aggressive dosing strategies were associated with
differences in response and toxicity data, as well as other markers of patient benefit.
With growing calls for the use of biologic, rather than toxic, endpoints in Phase I trials of
targeted biologic agents, limiting our sample to studies of cytotoxics seemed even more
valuable.33, 34, 38
There has been much optimism about the potential for these novel design
strategies to improve the risk benefit profile of phase I oncology trials for patients. The
rationale was that having fewer patients in lower dose levels, escalating the dose more
quickly and allowing patients to increase their own dose, would reduce the number of
patients receiving “sub-therapeutic” doses and enable more patients to have better
chances of achieving response.30, 37-39 Lending partial support to this assumption, a study
that looked at single agent trials of both cytotoxic and biologic agents found that studies
that allowed intra-patient dose escalation predicted for an increased response rate with no
added risk of toxicity.1

We found, however, that these methods did not seem to provide any advantage in
the setting of single agent trials of cytotoxic drugs. Allowing intra-patient dose
escalation, or using fewer patients in earlier, “sub-therapeutic” dose levels, was neither
associated with any increased rates of response, nor with an increased proportion of
patients receiving the recommended phase II dose. Also, trials employing these strategies
required, on average, the same number of patients as their more standard alternatives.
Yet, they do not appear to be any more harmful than standard protocols and may still
confer psychological benefits to patients enrolled. Patients may be encouraged by the
knowledge that all participants have the potential to receive the highest possible dose and
that they would be limited in doing so only on the basis of toxicity rather than by study
design constraints.
A more concerning result was that aggressive titration designs were associated
with larger percentages of patients who experienced severe, or life threatening toxicity as
compared to trials that used traditional “modified Fibonacci” dose escalations, and this
relationship was confirmed for hematologic toxicity in multivariate analysis. This data
suggests that aggressively increasing the dose of a cytotoxic agent in a single agent phase
I trial adversely impacts the risk-benefit ratios that enrolled patients face. While more
research is needed to confirm this finding, investigators ought to inform their patients of
this observation, and give greater consideration to other methods of reducing the number
of patients treated at “sub-therapeutic” dose levels.
Our results for conservative dose escalation strategies appeared counter-intuitive
at first. We would have expected trials that increased doses more slowly to be associated
with more patients being exposed to “less potent” forms of the drug and therefore with

lower rates of response and toxicity and higher numbers of patients receiving “subtherapeutic” doses. Quite the contrary, these studies were associated with increased
toxicity rates, higher response rates and a greater percentage of patients who received the
recommended phase II dose. One way to account for this data is to consider the high
likelihood that investigators deliberately chose a more conservative design because of
some prior indication as to the potency of the particular agent. Of course, prior FDA
approval would be a major reason to do so. This is supported by the fact that of the
studies that tested agents already approved by the FDA, 65% (24/38) used a conservative
titration design, while only 32% of studies which tested novel agents used conservative
titration designs. Another outcome that highlights the overlap between trials that used
conservative design strategies and those that tested FDA approved agents is that only
these two trial categories required significantly fewer patients to complete their trials.
This study has several limitations. First, our study samples were imperfect. Part I
reported the results of a meta-analysis that was restricted to 2002. It is possible that
studies published in 2002 were not representative of all Phase I oncology trials, although
the similarities between our results and other recent meta-analyses reduces this concern.
Our sample of studies was also heterogeneous with regard to the agents studied as well as
cancer types. This consideration provided the impetus to limit our investigation in Part II
to single agent cytotoxic drugs, in order to minimize the impact that sample heterogeneity
would have on our results. In doing so, however, the generalizability of our results is
limited and does not extend to the variety of design innovations currently being used and
studied in non cytotoxics, most notably biological agents and targeted therapies. Lastly,

although not currently available, patient level data would have been preferable to trial
level data.
The lack of uniform reporting standards as well as publication biases may have
also led to overestimated or underestimated response and toxicity rates. However, since
publication of Phase I studies is not dependent on response rates, and there was no
indication of a suppression of adverse mortality data, publication bias may be less likely
than in other types of meta-analysis.
Finally, we must always be cautious about establishing causality in a retrospective
analysis. Unfortunately, given the nature of phase I oncology trials, prospective studies
examining these different design strategies may be very difficult to undertake from both
methodological and practical standpoints.

CONCLUSION

Phase I oncology trials reflect the high stakes of investigative medicine. While
the potential for discovery and innovation for the betterment of our patients and society at
large is high, so is the potential for exploitation, misrepresentation and causing
unnecessary harm to our patients. An evaluation of how the interplay between the risks
and benefits of these trials impact on their ethics should be informed by the most current
and comprehensive data available. The primary objective of this thesis was to provide
this information and understand how it may answer some fundamental questions about
the risks and benefits of phase I oncology trials. By doing so, we have come to
understand two fundamental insights.

Firstly, all phase I oncology trials are not the same. Rather, they represent a
spectrum of different classes of agents and designs strategies that are often associated
with distinct clinical outcomes. Accounting for this variety is critical in trying to
evaluate the risk-benefit ratios that these trials offer participating patients, and in
considering the ethical questions involved.
Secondly, while some novel dosing strategies appear to have little impact on
clinical endpoints, others may in fact be harmful. The allowance of intra-patient dose
escalation and the use of fewer than three patients in initial dosage levels do not appear to
impact response or toxicity rates, the percentage of patients who receive the
recommended phase II “therapeutic” dose, or decrease the average number of patients
needed to complete a trial. Aggressive dose escalation designs expose patients to greater
risk of toxicity with no increased likelihood of benefit. These innovations do not seem to
deflect some of the most fundamental ethical challenges made against these trials, which
highlights the need for continued effort towards improving trial design and its impact on
our patients.
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TABLE 1: Response Rates of Phase I Oncology Trials published in 2002.
# of Trials

# Assessable for
Response

Complete Response Rate*
(CR) (%)

Response Rate*
(CR+PR) (%)

Total Response Rate*
(CR+PR+SD) (%)

Total

221

5362

3.8 (2.8, 5.0)

19 (17, 22)

48 (44, 52)

Chemotherapy Cytotoxic

173

4268

4.2 (3.1, 5.7)

21 (18, 25)

50 (45, 55)

Immunomodulator

12

216

6.2 (2.5, 11)

14 (6.0, 26)

43 (29, 59)

Receptor/Signal
Transduction

11

377

3.5 (1.0, 8.4)

13 (6.1, 24)

37 (24, 53)

Anti-Angiogensis

9

225

1.0 (0.1, 2.8)

11 (4.1, 22)

38 (24, 55)

Gene Therapy

3

63

1.7 (<0.1, 6.1)

21 (10, 34)

33 (20, 46)

Vaccine

13

213

0.5 (<0.1, 2.0)

2.9 (1.0, 5.6)

44 (30, 59)

*Numbers in CR, CR+PR, and CR+PR+SD columns are rates with 95% credible intervals in parentheses.

TABLE 2: Response and Mortality Rates for Combinations of Agents in Phase I Oncology Trials.

# of
Trials
221

Total
chemo
Single
Investigational
Agent Alone

nonchemo

40
35

Complete
Response
Rate (CR)

Response
Rate
(CR+PR)

Total
Response Rate
(CR+PR+SD)

Total
Deaths

3.8
(2.8, 5.0)

19
(17, 22)

48
(44, 52)

63

0.6
(0.2, 1.1)
1.7
(0.6, 3.7)

4.8
(2.8, 7.8)
7.7
(3.8, 14)

26
(21, 31)
38
(28, 49)

11
3

Toxic
Death
Rate

Grade 3-4
non-heme
toxicity
22
(19, 24)

Grade 4
heme
toxicity
19
(16, 23)

1.0
(0.5, 1.6)
0.4
(0.1, 1.0)

19
(14, 24)
18
(12, 25)

10
(6.1, 15)
2.8
(0.1, 6.5)

1.1
(0.8, 1.6)

Combination of Investigational
and Commercial agents

23

1.4
(0.5, 2.8)

14
(9.3, 20)

49
(39, 59)

5

0.9
(0.3, 1.8)

24
(18, 31)

16
(9.8, 24)

Commercial
(No Investigational) Agents

121

5.9
(4.3, 7.9)

29
(25, 33)

59
(54, 64)

44

1.6
(1.0, 2.4)

24
(20, 27)

29
(24, 35)

* Numbers are rates with 95% credible intervals in parentheses.
** There were only two studies with multiple investigational agents. These two studies were excluded because the number of studies
was too few to make inferences.

TABLE 3: Multiple regression analysis of Phase I Oncology Trials.

Response Rate
(CR+PR)
OR (95% PI)

Total Response Rate
(CR+PR+SD)
OR (95% PI)

Grade 3/4
non-hematological toxicity

Grade 4
hematological toxicity

OR (95% PI)

OR (95% PI)

1.0 (ref)

1.0 (ref)

1.0 (ref)

1.0 (ref)

investigational cytotoxic
agent

0.77
(0.36, 1.55)

0.65
(0.36, 1.16)

1.09
(0.64, 1.88)

5.26
(1.99, 14.0)

Non- Investigational
cytotoxic agent
US for-profit

5.16
(2.72, 9.58)
(ref)

2.23
(1.32, 3.74)
(ref)

1.62
(1.04, 2.64)
(ref)

18.9
(7.92, 48.4)
(ref)

US non-profit

1.51
(0.65, 3.39)
0.61
(0.24, 1.43)
1.68
(0.93, 3.22)
1.72
(0.76, 3.90)
0.34
(0.16, 0.75)
0.54
(0.33, 0.87)

0.90
(0.47, 1.63)
0.44
(0.23, 0.87)
1.57
(0.92, 2.56)
2.34
(1.17, 4.76)

0.98
(0.57, 1.79)
1.56
(0.81, 3.06)
1.39
(0.89, 2.27)
0.85
(0.44, 1.62)

0.85
(0.28, 2.45)
0.39
(0.11, 1.39)
1.77
(0.84, 3.97)
2.29
(0.84, 6.75)
0.32
(0.10, 1.06)

0.63
(0.41, 0.95)

2.14
(1.49, 3.19)

non-cytotoxic agent

US other
Europe
Other nations
Solid Tumor
Prior chemo

TABLE 4: Deaths and Toxicities* in Phase I Oncology Trials published in 2002.

Number
of Trials

Number of
Participants
assessable for
toxicity

Total
Number
of
Deaths**

Total

221

6,008

63

Chemotherapy Cytotoxic

173

4,724

Immunomodulator

12

Receptor/Signal Transduction

Toxic Death
Rate (%)*

Grade 4
hematologic
toxicity (%)*

1.1
(0.8, 1.6)

Grade 3-4
nonhematologic
toxicity (%)*
22
(19, 24)

59

1.3
(0.9, 1.9)

23
(20, 25)

25
(21, 29)

261

1

11

404

2

Anti-Angiogensis

9

251

0

Gene Therapy

3

63

1

Vaccine

13

305

0

0.9
(0.1, 2.4)
0.8
(0.2, 2.1)
0.4
(<0.1, 1.4)
2.0
(0.2, 7.6)
0.4
(<0.1, 1.3)

18
(13, 24)
23
(18, 30)
22
(13, 33)
31
(20, 44)
9.0
(2.0, 21)

8.3
(5.2, 12)
5.6
(1.6, 14)
2.0
(0.5, 4.1)
13
(6.1, 22)
0.7
(0.1, 1.9)

19
(16, 23)

*Numbers in toxic death rate, grade 3-4 non-hem toxicity and grade 4 heme toxicity columns are rates with 95% credible intervals in
parentheses.
**Includes possible, probable and definite deaths.

TABLE 5: Sponsorship of Phase I Oncology Trials published in 2002.

Number of
Trials

Complete Response
Rate (CR) (%)

114
Total
Profit

54

Nonprofit

34

Other
(Not
reported)

26

Response Rate
(CR+PR) (%)

Total Response Rate
(CR+PR+SD) (%)

Total
Deaths

35

3.5
(2.3, 5.1)
5.0
(2.9, 8.0)
3.2
(1.8, 5.5)

14
(11, 18)

38
(33, 43)

17
(12, 23)
16
(10, 23)

44
(36, 52)
39
(31, 48)

20

0.8
(0.2, 1.6)

8.0
(4.2, 12)

27
(20, 34)

10

5

Toxic
Death
Rate (%)

Grade 4
hematologic
toxicity (%)

1.3
(0.8, 2.1)

Grade 3-4
nonhematologic
toxicity (%)
20
(17, 23)

1.4
(0.8, 2.4)
0.7
(0.2, 1.3)

19
(15, 24)
19
(13, 25)

16
(11, 24)
12
(6.4, 20)

2.3
(0.7, 5.1)

24
(19, 30)

5.4
(3.1, 8.4)

13
(10, 18)

TABLE 6: Geography in Phase I Oncology Trials published in 2002.
Number of
Trials

Total

221

U.S.

114

Europe

80

Other

27

Complete
Response Rate
(CR) (%)

Response Rate
(CR+PR) (%)

Total Response
Rate
(CR+PR+SD)

Total
Deaths

Toxic Death
Rate (%)

3.8
(2.8, 5.0)

19
(17, 22)

48
(44, 52)

63

14
(11, 18)

38
(33, 43)

24
(19, 30)

56
(49, 62)

25
(18, 34)

64
(53, 75)

3.5
(2.3, 5.1)
4.6
(2.9, 7.0)
2.6
(1.3, 4.2)

1.1
(0.8, 1.6)

Grade 3-4 nonhematologic
toxicity (%)
22
(19, 24)

Grade 4
hematologic
toxicity (%)
19
(16, 23)

1.3
(0.8, 2.1)

20
(17, 23)

13
(10, 18)

23

1.1
(0.7, 1.7)

25
(21, 30)

25
(19, 32)

5

0.8
(0.3, 1.7)

18
(12, 23)

26
(20, 34)

35

TABLE 7: Patient Characteristics for PART II

Demographics

Number of patients (%)

# of patients
# evaluable for toxicity
# evaluable for response

4,532
4,350
4,027

Male/Female
Median Age (age range)*
25th percentile/75th percentile

2610:1922 (58/42)
56.5 (0.9-90)
53/61

Prior Treatment History**
Prior Chemotherapy
Prior Radiation
Prior Surgery/Transplant

3,084 (76)
1135 (28)
758 (19)

No Prior Cancer Treatment

105 (2.5)

* Calculated as the median of the median age.
**Percentages were determined with denominator of 4,051 patients for whom these data were provided.

TABLE 8: Frequency and Bivariate Analysis

Study Design

% [Number] of
Studies

Complete + Partial
Response*
% [N]
(95% CI)

Total

100% [149]

3% [141]

Conservative

40% [59]

Traditional

26% [37]

Aggressive

34% [49]

6% [55]
(4-9)
2% [35]
(1-3)
1% [47]
(1-2)

Yes
No

22% [32]
78% [112]

2% [29]
3% [108]

Complete + Partial
Response
+ Stable Disease
% [N]
(95% CI)
25% [127]

Dose Escalation
32% [46]
(25-39)
21% [32]
(15-28)
23% [45]
(17-29)
Intra-patient Dose Escalation
24% [27]
26% [97]

Grade 4
Hematological
Toxicity
% [N]
(95% CI)

Grade
3/4 Non
Hematological
Toxicity
% [N]
(95% CI)

Patients Receiving
Recommended
Phase II Dose
% [N]
(95% CI)

15% [124]

17% [155]

60% [134]

17% [50]
(13-21)
10% [30]
(7-14)
17% [41]
(13-21)

20% [54]
(15-25)
13% [33]
(9-18)
17% [45]
(13-22)

71% [52]
(63-77)
46% [35]
(37-57)
55% [45]
(46-63)

15% [24]
15% [97]

16% [28]
17% [103]

66% [30]
57% [101]

Minimum Patients per dose for first course of therapy
<3 patients

28% [40]

2% [38]

3+ patients

72% [105]

26% [38]

FDA approved
not FDA approved

74% [111]

16% [32]

17% [35]

65% [39]

3% [100]

20% [36]
(14-26)
28% [90]
(24-33)
FDA approved agent

14% [90]

17% [98]

57% [94]

10% [34]
(6-17)
2% [107]
(1-3)

40% [29]
(31-49)
22% [98]
(19-26)

18% [30]
(13-23)
14% [94]
(12-16)

19% [33]
(14-25)
16% [102]
(14-19)

65% [35]

*Numbers in columns are rates with number of studies in brackets and 95% credible intervals in parentheses.

58% [99]

TABLE 9: Mean # patients needed for completion of phase I trials
Category of dosing strategy or
agent

Dose Escalation

IPDE

Minimum
Patients per
dose in first
course
Approval Status

Mean # pts needed per
trial

Conservative

26.2

Traditional

31.9

Aggressive

33.6

Allowed

30.4

Not Allowed

29.9

<3

31.7

3 or more

30.1

FDA approved

25.2

unapproved

32.2

TABLE 10: Comparison of Response and Toxicity Rates in Published Meta Analyses
Lead Author

Type of
trials/agents
studied

Years
Studied

# studies
(# patients)

Toxic
deaths
(%)

Grade 4
Hematologic
toxicity (%)

Grade ¾
nonhematologic
toxicity (%)

CR
(%)

PR
(%)

CR
+PR
+SD
(%)

Decoster24

Single agent
cytotoxics

1972-1987

211 (6,639)

0.5

N/R

N/R

0.3

4.2

N/R

Von Hoff22

Single agent
cytotoxics

1970-1983

228 (7,960)

N/R

N/R

N/R

1.0

5.0

N/R

Estey23

Single agent
cytotoxics

1974-1982

187 (6,447)

N/R

N/R

N/R

0.7

3.5

N/R

Itoh25

Single agent
cytotoxics

1981-1991

56 (2,200)

N/R

N/R

N/R

1.1

2.2

N/R

Roberts1

All single agent

1991-2002

213 (6,474)

0.54

10.3 overall

3.8 overall

N/R

Horstmann28

All

1991-2002

460 (11,935)

0.49

14.3 overall

3.1

7.5

34.1

Current Study

All

2002

221 (6,008)

1.1

3.8

15.2

48.0

19.0

Abbreviations: N/R not recorded; CR complete response; PR partial response; SD stable disease

22.0

Figure 1: Study Selection

Potentially relevant phase I
oncology reports identified in
literature search (n=955)

Studies which conformed to
standard phase I chemotherapy
trial design (n=666)

Excluded because fundamental
study design was not standard
phase I chemotherapy trial*
(n=289)

Excluded because tested more
than one agent (n=402)

Single agent trials (n=264)

Excluded because tested agent in
tnon cytotoxic class** (n=115)
Phase I oncology studies meeting
all inclusio n criteria (n=149)

* Includes studies which were not cancer related, not Phase I studies, or dose finding studies; those that did not assess the safety
profile of the agent; those that included the use of radiotherapy, cryotherapy or photodynamic therapy; and those for which the trial
data was inaccessible or incomplete.

** This includes signal transduction inhibitors, angiogenesis inhibitors, immunotherapy and gene therapy.

Figure 2A and 2B

Figure 2C and 2D
Figure 2. Response rates and toxicity of phase 1 oncology trials published in 2002 stratified by chemotherapy, immunomodulator,
receptor/signal transduction, gene therapy, angiogenesis, vaccines. Panel A. CR+PR Panel B. Rate of Toxic Deaths Panel C. Nonhematological Grade 3/4 toxicity Panel D. Hematological Grade 4 toxicity.
Agent: black=chemotherapy, red=immmodulator, green=receptor/signal, blue=angio-genesis, light blue=gene therapy, pink=vaccines.

Figure 3A and 3B

Figure 3C and 3D
Figure 3. Response rates and toxicities of phase 1 oncology trials published in 2002 stratified by sponsorship (profit, non-profit, other)
Panel A. CR+PR Panel B. Rate of Toxic Deaths Panel C. Non-hematological Grade 3/4 toxicity Panel D. Hematological Grade 4
toxicity. Support: black=drug/device manufacturer, red=not for profit, green=other/not-specified.

Figure 4: Frequency of Novel Design Strategies by Year

% of total
studies

40
35
30
25
20
15
10
5
0

2002
2003
2004

IPDE

Agg

<3 ppd

Novel design type
IPDE: Studies that allowed intra-patient dose escalation
Agg: Studies that used an aggressive titration design
<3ppd: Studies that used lass than 3 patients per dose in initial dose levels

Figure 5: Multivariate regression analysis of association
between FDA approval status and dose escalation strategy with
outcome of rate of complete response (CR) + partial response
(PR).

Figure 6: Multivariate Regression Analysis of association
of FDA approval status and dose escalation strategy with
rate of complete response (CR), partial response (PR) and
disease stabilization (SD) stratified by minimum patients
required per dose of either >2 or <3.

APPENDIX: Search Criteria for Parts 1 and 2

PART 1: The Medline database was searched to identify Phase I clinical oncology trials published in 2002. The search criteria were
as follows: neoplasms (mh) NOT (review (pt) OR meta-analysis (pt) OR editorial (pt) OR practice guideline (pt) OR (clinical trial,
Phase ii (pt) NOT clinical trial, Phase i (pt)) OR radiotherapy (mh)) AND (clinical trial, Phase i (pt) OR "Phase i") AND (drug therapy
(mh) OR antineoplastic agents (mh) OR drug evaluation (mh) OR cancer vaccines (mh) OR adjuvants, immunologic (mh) OR signal
transduction (mh) OR angiogenesis inhibitors (mh) OR gene expression regulation, neoplastic (mh) OR gene therapy (mh) OR cell
transplantation). The search was performed on all fields of the database, but was limited to articles that were written in the English
language and were published in 2002. Also, the publication type was defined as ‘clinical trials’ and the subset was designated as
‘cancer.’

PART 2: The Medline database was searched to identify single agent phase I oncology trials of cytotoxic agents published between
2002 and 2004. The search criteria initially included antineoplastic or chemotherapy or cytotoxic and was limited to humans and the
English language. The subset was defined as ‘cancer,’ the publication type was designated as ‘clinical trial - phase I’ and the year of
interest was selected.

